Business Wire

DealCloud Appoints James Brierley as Solutions Engineer for EMEA

23.11.2020 11:00:00 EET | Business Wire | Press release

Share

DealCloud, the premier provider of deal, relationship, and firm management software to capital market firms, announces the appointment of James Brierley as Solutions Engineer, based in London. With more than 7 years of experience across asset classes with a technology focus, Brierley’s appointment will help fuel the DealCloud Solutions Engineering program in the EMEA region.

Prior to joining DealCloud, Brierley led technology efforts at Park Square Capital, a leading private debt manager. He worked across the organization with a remit of procuring best-in-class technology solutions to support the next stage of Park Square’s growth.

Brierley’s first-hand knowledge of the available technology in the private capital markets will ensure DealCloud clients — both current and prospective — are well-placed to maximize the value that a solution like DealCloud can provide.

“Having witnessed the shortcomings of generic CRM firsthand, I was fortunate enough to be introduced to DealCloud,” he commented. “Frustratingly, one of the bigger hurdles facing my previous firm — like many in the industry — hinged on being tied into a contract with the aforementioned CRM. After researching the alternatives, DealCloud seemed to solve so many issues facing the firm that I was able to put together a strong business case for migration.”

As a former DealCloud client, Brierley enjoys a unique perspective. “Having gone through the DealCloud sales process, implementation, and account management, I’m well-placed to help our clients connect the dots of their ecosystems and keep up with the ever-growing demands facing firms in the private capital markets,” he remarked.

“We had the pleasure of working with James as a client for several years before he joined us to lead our Solutions Engineering efforts in EMEA,” said Michael Santos, Vice President of EMEA sales for DealCloud. “The volume of large and complex transactions in our industry is on the rise, and DealCloud has taken on a life of its own, expanding outside of just CRM and deal management. James’s industry and product knowledge will ensure our clients are poised to tap into the full potential of the DealCloud solution. His ability to solve problems, break down issues, and rebuild better than before is exactly what we were looking for in this role.”

Brierley began his career at Islandbridge Capital and later joined the operations team at Impax Asset Management. He holds a bachelor’s degree with honors in accounting and finance from Durham University. Outside the office, Brierley is a keen sportsman who particularly enjoys rugby and squash, and describes himself as a born-again cricketer.

About DealCloud

DealCloud, an Intapp company, provides a single-source deal, relationship, and firm management platform to enable more than 900 clients to power their deal-making processes from strategy to origination to execution. We offer fully configurable solutions purpose-built for the complex relationships and structures of private equity and growth capital firms, investment banks, private and publicly traded companies, debt capital providers, and other investors. For more information, visit dealcloud.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Alex Nye
anye@stantonprm.com
646-502-3598

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye